Article Text

Download PDFPDF

P635 The enhanced gonococcal antimicrobial surveillance program (EGASP) in the philippines, 2018
  1. Emily Weston1,
  2. Mark Angelo Amoroso2,
  3. Noel Palapayon2,
  4. Genesis Samonte2,
  5. Celia Carlos3,
  6. Cau Pham1,
  7. Teodora Wi4
  1. 1US Centers for Disease Control and Prevention, Division of STD Prevention, Atlanta, USA
  2. 2Philippines Department of Health, National HIV/AIDS and STI Surveillance and Strategic Information Unit, Epidemiology Bureau, Manila, Philippines
  3. 3Philippines Department of Health, Research Institute of Tropical Medicine, Manila, Philippines
  4. 4World Health Organization, Department of Reproductive Health and Research, Geneva, Switzerland


Background In July 2018, the Philippines Department of Health, the Centers for Disease Control and Prevention and World Health Organization implemented the Enhanced Gonococcal Antimicrobial Surveillance Program (EGASP). The Philippines is the second country to implement EGASP to monitor antimicrobial susceptibility trends of Neisseria gonorrhoeae (GC).

Methods Men with urethral discharge were enrolled at 4 participating sentinel clinics in Metro Manila. Symptomatic men had demographic and clinical data collected; two urethral swabs were collected for gram stain and culture. All positive cultures had antimicrobial susceptibility testing (AST) performed by 2 participating reference laboratories to determine minimum inhibitory concentrations for Cefixime, Ceftriaxone, Azithromycin, and Gentamicin using E-test.

Results From July – September 2018, 92 specimens were collected from symptomatic men; 61 (66%) were culture confirmed and all GC isolates had AST. Among 60 men with at least one GC infection, 32 (53%) were classified as men who have sex with women only, 15 (25%) as men who have sex with men and 13 (22%) were men who have sex with men and women. The median age of men was 24 years (range 15 –52 years), 12 (20%) had antibiotic use in the last 2 weeks, 4 (7%) had travel in the last 30 days, and 43 (72%) received combination therapy of Ceftriaxone (250 mg, 500 mg or 1 g) or Cefixime 400 mg PLUS Doxycycline 100 mg or Azithromycin 1 g. Only 6 (10%) did not have treatment documented. No isolates had elevated MICs to the antimicrobials tested.

Conclusion We report on the first months of data from EGASP Philippines demonstrating the feasibility of collecting standardized and systematic epidemiological and laboratory data. All isolates were susceptible to all tested antimicrobials. Continued surveillance is critical to monitor for emerging resistance and to inform local and regional treatment recommendations.

Disclosure No significant relationships.

  • Neisseria gonorrhoeae
  • surveillance
  • antimicrobial resistance

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.